Trials / Completed
CompletedNCT03469934
Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma
Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- AnaptysBio, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a proof of concept study designed to assess the effects of a single intravenous dose of etokimab compared to placebo in adult participants with severe eosinophilic asthma. This study will also assess the safety and tolerability of etokimab in adult participants with severe eosinophilic asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Etokimab | Administered on Day 1 over 1 hour by IV infusion |
| DRUG | Placebo | Administered on Day 1 over 1 hour by IV infusion |
Timeline
- Start date
- 2017-11-14
- Primary completion
- 2018-10-30
- Completion
- 2018-10-30
- First posted
- 2018-03-19
- Last updated
- 2023-08-16
- Results posted
- 2023-08-16
Locations
7 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03469934. Inclusion in this directory is not an endorsement.